HCM Screening Yield (Community Athlete) Calculator
Screening inputs
Use locally appropriate prevalence and test-performance estimates.
About this screening model
This calculator combines assumed HCM prevalence with the sensitivity and specificity of an ECG-based screening strategy to estimate expected screening outcomes in a defined cohort.
How the model works
- Expected HCM cases = cohort size × prevalence.
- True positives = expected HCM cases × sensitivity.
- False negatives = expected HCM cases − true positives.
- True negatives = expected non-cases × specificity.
- False positives = expected non-cases − true negatives.
- PPV = TP / (TP + FP); NPV = TN / (TN + FN).
- Yield per 1,000 = TP / cohort size × 1,000; NNS = cohort size / TP.
Choosing assumptions
Important about the prefilled values: the initial sensitivity (93%) and specificity (96%) are illustrative starting assumptions only; they are not universally validated HCM-specific estimates. Replace them with estimates appropriate to the population and screening pathway being evaluated.
Use prevalence and test-performance estimates appropriate to the age, athletic population, ECG interpretation criteria, and downstream diagnostic pathway being evaluated. A commonly cited estimate of approximately 1 in 500 refers to unexplained asymptomatic hypertrophy in young adults in the United States; it should not automatically be treated as the prevalence of confirmed HCM in every community athlete cohort.
Evidence reporting performance of ECG screening for a composite of potentially lethal cardiovascular disorders does not necessarily provide HCM-specific sensitivity and specificity. Enter locally justified estimates where available and perform sensitivity analyses when uncertainty is substantial.
Clinical context & limitations
ECG screening may identify electrical or structural-disease patterns that warrant further evaluation, but a screening ECG is not a definitive diagnostic test for HCM.
- Results depend strongly on the assumed prevalence, sensitivity, and specificity.
- False-positive screens require appropriate secondary assessment; this model does not estimate cost, access, or downstream testing burden.
- A normal ECG does not exclude all HCM or other causes of sudden cardiac arrest in athletes.
- The model does not include age-specific prevalence, repeated screening, competing diagnoses, incomplete follow-up, or time-to-diagnosis.
- Do not use these estimates alone to determine sports eligibility or individual clinical management.
Selected references
Clinical notes
Document key findings and keep a structured record for your own reference.
My notes
Review, edit, or remove notes saved in this browser.
Report an issue
Your feedback helps us improve the reliability and usability of this clinical tool.